These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24971673)

  • 1. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Elgström E; Bäck T; Ohlsson T; Jensen H; Nilsson R; Lindegren S; Tennvall J
    Cancer Biother Radiopharm; 2014 Aug; 29(6):238-46. PubMed ID: 24971673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Mar; 27(2):134-40. PubMed ID: 22229635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    Mårtensson L; Wang Z; Nilsson R; Ohlsson T; Senter P; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7104s-7108s. PubMed ID: 16203809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Apr; 27(3):175-82. PubMed ID: 22417248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
    Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
    Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in cell death markers during (177)Lu-mAb radioimmunotherapy-induced rejection of syngeneic rat colon carcinoma.
    Elgström E; Ljungberg O; Eriksson SE; Orbom A; Strand SE; Ohlsson TG; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2014 May; 29(4):143-52. PubMed ID: 24693940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
    Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
    J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
    Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
    Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
    Eriksson SE; Bäck T; Elgström E; Jensen H; Nilsson R; Lindegren S; Tennvall J
    EJNMMI Res; 2013 Apr; 3(1):23. PubMed ID: 23557183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
    Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
    Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
    Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
    Zalutsky MR; Vaidyanathan G
    Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
    Garkavij M; Tennvall J; Strand SE; Sjögren HO; JianQing C; Nilsson R; Isaksson M
    J Nucl Med; 1997 Jun; 38(6):895-901. PubMed ID: 9189138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
    Vallabhajosula S; Goldsmith SJ; Kostakoglu L; Milowsky MI; Nanus DM; Bander NH
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
    Schoffelen R; van der Graaf WT; Franssen G; Sharkey RM; Goldenberg DM; McBride WJ; Rossi EA; Eek A; Oyen WJ; Boerman OC
    J Nucl Med; 2010 Nov; 51(11):1780-7. PubMed ID: 21051650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
    Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.